Objective. To compare antiplatelet efficacy of original clopidogrel and its generic analogue after implantation of Russian drug-eluting stents. Material and methods. Considering ADP-induced platelet aggregation, we compared aggregation in 3 and 30 days after intake of original and generic clopidogrel. Results. After 3 days, ADP-induced platelet aggregation was 36.5% and 39.1%, after a month — 38.9% and 43.7%, respectively. There were no major cardiac events (cardiac death, non-fatal acute myocardial infarction, stroke, stent thrombosis, stent restenosis, repeated target vessel revascularization, recurrence or progression of angina pectoris) throughout 12-52 months after stenting. Conclusion. We found no significant between-group difference in ADP-induced platelet aggregation and incidence of major cardiac events.
13 May 2024 in Cardiovascular Therapy and Prevention
Management of multimorbid patients is challenging, despite advances in pharmacotherapy and widespread use of surgical treatment. The combination of diseases such as coronary artery disease leading to heart failure, hypertension, type 2 diabetes and chronic kidney disease requires an individualized approach to the patient. Adjuvant non-invasive therapies could facilitate the management of such patients. In addition, the use of longer-term non-pharmacological treatment is associated with prolonged follow-up by medical personnel, which can improve patient adherence to therapy and, thus, their quality of life.This article presents a case of long-term follow-up and complex management of a patient with multimorbid pathology, including heart failure of ischemic etiology, with the addition of enhanced external counterpulsation in intermittent mode to therapy.